Orion Biotechnology is a clinical stage company that is unlocking the therapeutic and market potential of a very large group of drug targets – called G Protein Cell Receptors (GPCRs) – with a new class of drugs enabled by the company’s proprietary discovery platform. Doctor McGowan has enjoyed a career focused on tackling major health challenges from within academia as well as with the NIH, WHO and within industry at companies like Gilead Sciences.
